Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 16Carcinoma, Non-Small-Cell Lung 8Urinary Bladder Neoplasms 4Liver Neoplasms 4Small Cell Lung Carcinoma 3Lung Neoplasms 3Colorectal Neoplasms 2Biliary Tract Neoplasms 2Urothelial Cancer 1Unresectable Hepatocellular Carcinoma 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Malignancies 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Hypertension, Portal 1Hepato Cellular Carcinoma 1Hematologic Neoplasms 1Fibrosis 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma 1

Interventions

Cisplatin 15pembrolizumab 14Magnetic Resonance Spectroscopy 13Specimen Handling 12Carboplatin 10Platinum 81,2-diaminocyclohexaneplatinum II citrate 8Paclitaxel 7durvalumab 6Radiotherapy, Intensity-Modulated 6Cetuximab 6cemiplimab 5Radiotherapy 5Radiation 5Pemetrexed 5Nivolumab 5Biopsy 5Ipilimumab 4Fluorouracil 41-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 4(225)Ac-DOTA-c(RGDyK) 4poly ICLC 3osimertinib 3atezolizumab 3Taxes 3Oxaliplatin 3Docetaxel 3ipatasertib 2fludarabine phosphate 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × tremelimumab × 90 days × Clear all
NCT06564623 2026-05-08

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Recruiting
25 enrolled
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡